Burgstahler David F
Venture Investor/General Partner at RVL Pharmaceuticals plc; Director at LNTH; Director, 10% owner at ANGO
- Sold, on record
- $258M
- Dollars the filings state
- Form 4 sales
- 12
- Latest Sep 7, 2017
- Form 144 notices
- 2
- Proposed sales
- Companies
- 3
- Filed as an executive or holder
Companies
- RVL Pharmaceuticals plcVenture Investor/General Partner
- LNTHLantheus Holdings, Inc.Director
- ANGOANGIODYNAMICS INCDirector, 10% owner
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale LNTHUnusualJun 20, 2017 2017
Sold 3M shares at $14.87 ($44.6M)
Burgstahler David F, Director, 10% owner
Sold 63% of holdings ($70.8M position)1.8M shares left1x usual sizeFiling
- 2 Form 4 sale LNTHUnusualAug 16, 2017 +57 days
Sold 140,846 shares at $17.27 ($2.4M)
Burgstahler David F, Director
Sold 53.5% of holdings ($4.5M position)122,492 shares left0x usual sizeFiling
- 3 Form 4 sale LNTHUnusualAug 28, 2017 +12 days
Sold 91,166 shares at $17.01 ($1.6M)
Burgstahler David F, Director
Sold 48.3% of holdings ($3.2M position)97,479 shares left0x usual sizeFiling
- 4 Form 4 sale LNTHUnusualAug 31, 2017 +3 days
Sold 230,685 shares at $17.25 ($4M)
Burgstahler David F, Director
Sold 77.9% of holdings ($5.1M position)65,263 shares left0.1x usual sizeFiling
- 5 Form 4 sale LNTHUnusualSep 6, 2017 +6 days
Sold 78,833 shares at $16.95 ($1.3M)
Burgstahler David F, Director
Sold 59.9% of holdings ($2.2M position)52,684 shares left0x usual sizeFiling
- 6 Form 4 sale LNTHUnusualSep 7, 2017 +1 day
Sold 102,958 shares at $16.56 ($1.7M)
Burgstahler David F, Director
Sold 72.9% of holdings ($2.3M position)38,269 shares left0.1x usual sizeFiling
- 7 Form 144 notice RVL Pharmaceuticals plcNoticeAug 24, 2023 +2177 days
Filed to sell 767,515 shares ($106k)
Burgstahler David F, Venture Investor/General Partner
No 10b5-1 planFirst sale on recordFiling
- 8 Form 144 notice RVL Pharmaceuticals plcNoticeSep 25, 2023 +32 days
Filed to sell 670,694 shares ($60k)
Burgstahler David F, Venture Investor/General Partner
No 10b5-1 planFirst sale on recordFiling
Every transaction
Loading transactions…
Sales and notices (14)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Sep 25, 2023 | Sep 25, 2023 | RVL Pharmaceuticals plc | Venture Investor/General Partner | Form 144 notice | 670,694 | $60k | Notice | SEC | |
| Aug 24, 2023 | Aug 24, 2023 | RVL Pharmaceuticals plc | Venture Investor/General Partner | Form 144 notice | 767,515 | $106k | Notice | SEC | |
| Sep 7, 2017 | Sep 11, 2017 | LNTH | Director | Form 4 sale | 102,958 | $1.7M | 72.9% | Unusual | SEC |
| Sep 6, 2017 | Sep 6, 2017 | LNTH | Director | Form 4 sale | 78,833 | $1.3M | 59.9% | Unusual | SEC |
| Aug 31, 2017 | Aug 31, 2017 | LNTH | Director | Form 4 sale | 230,685 | $4M | 77.9% | Unusual | SEC |
| Aug 28, 2017 | Aug 28, 2017 | LNTH | Director | Form 4 sale | 91,166 | $1.6M | 48.3% | Unusual | SEC |
| Aug 16, 2017 | Aug 16, 2017 | LNTH | Director | Form 4 sale | 140,846 | $2.4M | 53.5% | Unusual | SEC |
| Jun 20, 2017 | Jun 22, 2017 | LNTH | Director, 10% owner | Form 4 sale | 3M | $44.6M | 63.0% | Unusual | SEC |
| May 9, 2017 | May 11, 2017 | LNTH | Director, 10% owner | Form 4 sale | 3M | $40.2M | 53.6% | Unusual | SEC |
| Apr 12, 2017 | Apr 14, 2017 | ANGO | Director, 10% owner | Form 4 sale | 2.4M | $37.6M | 86.0% | Unusual | SEC |
| Mar 17, 2017 | Mar 21, 2017 | LNTH | Director, 10% owner | Form 4 sale | 3M | $36.6M | 46.6% | Unusual | SEC |
| Nov 21, 2016 | Nov 23, 2016 | LNTH | Director, 10% owner | Form 4 sale | 2.5M | $22.5M | 36.9% | Unusual | SEC |
| Nov 18, 2016 | Nov 22, 2016 | ANGO | Director, 10% owner | Form 4 sale | 2.1M | $32.8M | 67.3% | Unusual | SEC |
| Aug 5, 2016 | Aug 5, 2016 | ANGO | Director, 10% owner | Form 4 sale | 2.3M | $32.9M | 59.1% | Unusual | SEC |